Picoplatin is a new generation platinum-based chemotherapy agent that is in clinical development for multiple cancer indications,treatment combinations and by two routes of administration.It is designed to overcome platinum resistance associated with chemotherapy in solid tumors.Study data to date suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies in > 1,100 patients.Results to date suggest that hematologic events are common but manageable.Kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) are less frequent and less severe than is commonly observed with other platinum chemotherapy drugs.